TETRANEURON
Contact information
- Gene Therapy
Tetraneuron is driving a new paradigm in the treatment of neurodegenerative diseases through gene therapy. Founded in Madrid in 2012, the company combines pioneering research with strategic partnerships to bring to the clinic therapies capable of halting and reversing neurodegeneration, with the vision of transforming the global approach to these conditions.
TET-101 is an innovative gene therapy developed by Tetraneuron for the treatment of Alzheimer’s disease. Based on the E2F4DN protein, it targets multiple cellular mechanisms involved in the disease. Preclinical results demonstrate its ability to slow neurodegeneration and restore memory. Tetraneuron is currently progressing towards clinical trials to validate its safety and efficacy in patients.
- Advanced Therapies
- Neurodegenerative Diseases
- Ageing